Proton pump inhibitors and the risk of Clostridium difficileassociated disease: further evidence from the community

Cunningham, Richard
September 2006
CMAJ: Canadian Medical Association Journal;9/26/2006, Vol. 175 Issue 7, p757
Academic Journal
The article presents a commentary on the research previously published in the "Canadian Medical Association Journal" entitled "Proton Pump Inhibitor Use and Risk of Community-Acquired Clostridium Difficile-Associated Disease Defined by Prescription for Oral Vancomycin Therapy." It discusses the impact of the research findings on the alleged association of proton pump inhibitors with Clostridium difficile-associated disease.


Related Articles

  • Proton pump inhibitors increase risk of Clostridium infection.  // Reactions Weekly;8/21/2004, Issue 1015, p5 

    Discusses research being done on the significance of proton pump inhibitors to Clostridium difficile diarrhoea. Reference to a study by S. Dial et al., published in the July 6, 2004 issue of the "Canadian Medical Association Journal"; Background on the use of antibacterials in the treatment of...

  • Fluoroquinolone use a risk factor for CDAD.  // Reactions Weekly;1/14/2006, Issue 1084, p4 

    The article reports on the results of a cohort study regarding the association of the use of fluoroquinolones with a higher risk of Clostridium difficile-associated diarrhoea. Comparison of the use of fluoroquinolones with the use of other antibacterials, proton pump inhibitors, antacids and...

  • Use of Gastric Acid–Suppressive Agents and the Risk of Community-Acquired Clostridium difficile–Associated Disease. Dial, Sandra; Delaney, J. A. C.; Barkun, Alan N.; Suissa, Samy // JAMA: Journal of the American Medical Association;12/21/2005, Vol. 294 Issue 23, p2989 

    Context Recent reports suggest an increasing occurrence and severity of Clostridium difficile–associated disease. We assessed whether the use of gastric acid–suppressive agents is associated with an increased risk in the community. Objective To determine whether the use of gastric...

  • Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case--control studies. Dial, Sandra; Alrasadi, Khalid; Manoukian, Chantal; Huang, Allen; Menzies, Dick // CMAJ: Canadian Medical Association Journal;7/6/2004, Vol. 171 Issue 1, p33 

    Background: Antibiotic disruption of the normal intestinal flora is a well-known risk factor for Clostridium difficile-associated di-arrhea. Reduced gastric acidity has been suggested as a risk factor, and we hypothesized that proton pump inhibitors, be-cause of their potency, may be an...

  • Rabeprazole: A Viewpoint by Noriaki Takeguchi. Takeguchi, N. // Drugs;Feb1998, Vol. 55 Issue 2, p268 

    Presents a viewpoint on the efficacy of rabeprazole against acid-related disorders. Mechanism of action of the medication; Characteristics as a proton pump inhibitor.

  • Rabeprazole: A Viewpoint by Simmy Bank. Bank, S. // Drugs;Feb1998, Vol. 55 Issue 2, p268 

    Presents a viewpoint on the efficacy of rabeprazole against acid-related disorders. Mechanism of action; Characteristics as a proton pump inhibitor; Results of clinical trials on the medication.

  • Clinical Pharmacology of Proton Pump Inhibitors: What the Practising Physician Needs to Know. Robinson, Malcolm; Horn, John // Drugs;2003, Vol. 63 Issue 24, p2739 

    Proton pump inhibitors (PPIs) [omeprazole, lansoprazole, pantoprazole, rabeprazole and esomeprazole] are widely utilised for the treatment of gastro-oesophageal reflux disease, as well as other acid-related disorders. All PPIs suppress gastric acid secretion by blocking the gastric acid pump,...

  • Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy. Dial, Sandra; Delaney, J. A. Chris; Schneider, Verena; Suissa, Samy // CMAJ: Canadian Medical Association Journal;9/26/2006, Vol. 175 Issue 7, p745 

    Background: The association between the use of proton pump inhibitors and the risk of Clostridium difficile-associated disease (CDAD) is controversial. In this study we re-examined a previously reported association between the use of proton pump inhibitors and the development of...

  • Association of proton-pump inhibitors with outcomes in Clostridium difficile colitis. Cadle, Richard M.; Mansouri, Mohammad D.; Logan, Nancy; Kudva, Denise R.; Musher, Daniel M. // American Journal of Health-System Pharmacy;11/15/2007, Vol. 64 Issue 22, p2359 

    Purpose. The role of concurrent use of proton-pump inhibitors (PPIs) in the outcomes of treatment for Clostridium difficile colitis was studied. Methods. The records of inpatients at a large Veterans Affairs medical center in whom C. difficile colitis was diagnosed between June 2004 and July...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics